While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic ...

With FDA-requested toxicology reports in hand, Quantum is preparing to seek clearance for stating the first trial of Lucid-MS ...

Researchers have identified two compounds capable of repairing the protective myelin sheath damaged by multiple sclerosis, a major advance toward reversing nerve injury rather than just slowing it.

Treatment with Sanofi's frexalimab was seen in a study to safely maintain disease control over 2.5 years in adults with ...

DelveInsight's“ Multiple Sclerosis Pipeline Insight 2025 ” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Multiple Sclerosis pipeline landscape. It covers the ...

An update from BioNxt Solutions ( ($TSE:BNXT) ) is now available. BioNxt Solutions Inc., a bioscience company specializing in innovative drug ...

In a new study, researchers found that increased expression of gene PRDM1-S triggers loss of immune regulation in autoimmune conditions like multiple sclerosis (MS). The findings could pave the way ...

The project builds on earlier research involving a compound called indazole chloride, known for promoting remyelination and modulating the immune system in mouse models of MS. While effective, ...

FRANKFURT, Jan 13 (Reuters) - Merck KGaA said on Tuesday it had bought the rights to develop and market an experimental multiple sclerosis (MS) drug from British biotech company Apitope, expanding its ...

(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a ...

The lab is using AI to analyze complex biomedical data to improve drug development for many diseases, including MS and ...